PROK Stock Analysis: Buy, Sell, or Hold?
PROK - ProKidney Corp. Class A Ordinary Shares
$1.61
0.19 (13.38%)
â˛
5d:
+21.05%
30d:
+5.92%
90d:
-8.0%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When PROK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PROK is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PROK is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: PROK is currently trading at $1.61, which is considered slightly high relative to its 30-day fair value range of $1.46 to $1.63.
Technical Outlook: Technically, PROK is in a downtrend. Immediate support is located at $1.30, while resistance sits at $1.70. The stock is showing strong short-term momentum, up 13.4% recently.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.25 (+340.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PROK is in a downtrend. Immediate support is located at $1.30, while resistance sits at $1.70. The stock is showing strong short-term momentum, up 13.4% recently.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.25 (+340.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.46 -
$1.63
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.1%
All Signals
- NEUTRAL: Mixed technical signals (57/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+13.4%)
- BULLISH: Trading 340.1% below Wall St target ($6.25)
- WARNING: Composite score 53/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.46 -
$1.63
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.30
Resistance Level
$1.70
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.42
Wall Street Target
$6.25
(+340.1%)
Revenue Growth (YoY)
-32.1%
Share & Embed Analysis
Last updated: August 24, 2026 6:54 AM ET
Data refreshes hourly during market hours. Next update: 7:54 AM
Data refreshes hourly during market hours. Next update: 7:54 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PROK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
